A股異動 | 業績遜預期 樂普醫療跌超10% 創2015年4月以來新低
樂普醫療(300003.SZ)盤初跌超10%,股價跌破10元關口,且創下2015年4月以來新低,總市值186億元。公司上週五晚間公吿,上半年營業收入33.84億元,同比下降21.33%,歸屬於上市公司股東的淨利潤6.97億元,同比下降27.48%。公司三大主要業務板塊營收均同比減少。而由於產品管線老化等問題,樂普醫療預計藥品業務調整或將持續1-2個季度,製劑業務板塊營收可能降至15億-16億元左右。中金公司點評稱,由於零售業務承壓等因素,上半年和2季度業績低於我們的預期,關注後續邊際改善。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.